WallStreetZenWallStreetZen

NASDAQ: ALGS
Aligos Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ALGS

Based on 1 analyst offering 12 month price targets for Aligos Therapeutics Inc

Min Forecast
$70.00+1,415.15%
Avg Forecast
$70.00+1,415.15%
Max Forecast
$70.00+1,415.15%

Should I buy or sell ALGS stock?

Based on 1 analyst offering ratings for Aligos Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although ALGS's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates ALGS as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their ALGS stock forecasts and price targets.

ALGS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-31

1 of 1

Forecast return on equity

Is ALGS forecast to generate an efficient return?

Forecast return on assets

Is ALGS forecast to generate an efficient return on assets?

Company
-22.59%
Industry
36.07%
ALGS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ALGS earnings per share forecast

What is ALGS's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$8.66
Avg 2 year Forecast
-$11.95
Avg 3 year Forecast
-$15.49

ALGS revenue forecast

What is ALGS's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$39.5M+901.27%
Avg 2 year Forecast
$4.0M+1.39%
Avg 3 year Forecast
$239.0M+5,958.56%
ALGS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

ALGS revenue growth forecast

How is ALGS forecast to perform vs Biotechnology companies and vs the US market?

Company
187.85%
Industry
65.48%
Market
10.37%
ALGS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ALGS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ALGS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ALGS$4.62$70.00+1,415.15%Buy
PYPD$2.75$10.50+281.82%Buy
GBIO$0.42$8.50+1,938.37%Strong Buy
BRNS$0.71$3.00+322.54%Buy
INKT$7.26$19.50+168.60%Buy
View Top Biotech Stocks

Aligos Therapeutics Stock Forecast FAQ

Is Aligos Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ALGS) stock is to Buy ALGS stock.

Out of 1 analyst, 0 (0%) are recommending ALGS as a Strong Buy, 1 (100%) are recommending ALGS as a Buy, 0 (0%) are recommending ALGS as a Hold, 0 (0%) are recommending ALGS as a Sell, and 0 (0%) are recommending ALGS as a Strong Sell.

If you're new to stock investing, here's how to buy Aligos Therapeutics stock.

What is ALGS's earnings growth forecast for 2025-2027?

(NASDAQ: ALGS) Aligos Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Aligos Therapeutics's earnings in 2025 is -$131,211,000.On average, 3 Wall Street analysts forecast ALGS's earnings for 2025 to be -$52,949,933, with the lowest ALGS earnings forecast at -$97,767,833, and the highest ALGS earnings forecast at -$8,009,747. On average, 3 Wall Street analysts forecast ALGS's earnings for 2026 to be -$73,045,839, with the lowest ALGS earnings forecast at -$103,637,571, and the highest ALGS earnings forecast at -$54,845,370.

In 2027, ALGS is forecast to generate -$94,680,106 in earnings, with the lowest earnings forecast at -$128,278,245 and the highest earnings forecast at -$61,081,967.

What is ALGS's revenue growth forecast for 2025-2028?

(NASDAQ: ALGS) Aligos Therapeutics's forecast annual revenue growth rate of 187.85% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Aligos Therapeutics's revenue in 2025 is $3,945,000.On average, 2 Wall Street analysts forecast ALGS's revenue for 2025 to be $241,515,285, with the lowest ALGS revenue forecast at $24,457,244, and the highest ALGS revenue forecast at $458,573,325. On average, 1 Wall Street analysts forecast ALGS's revenue for 2026 to be $24,457,244, with the lowest ALGS revenue forecast at $24,457,244, and the highest ALGS revenue forecast at $24,457,244.

In 2028, ALGS is forecast to generate $1,461,381,472 in revenue, with the lowest revenue forecast at $1,461,381,472 and the highest revenue forecast at $1,461,381,472.

What is ALGS's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ALGS) forecast ROA is -22.59%, which is lower than the forecast US Biotechnology industry average of 36.07%.

What is ALGS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ALGS price target, the average ALGS price target is $70.00, with the highest ALGS stock price forecast at $70.00 and the lowest ALGS stock price forecast at $70.00.

The Wall Street analyst predicted that Aligos Therapeutics's share price could reach $70.00 by Mar 31, 2026. The average Aligos Therapeutics stock price prediction forecasts a potential upside of 1,415.15% from the current ALGS share price of $4.62.

What is ALGS's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ALGS) Aligos Therapeutics's current Earnings Per Share (EPS) is -$20.94. On average, analysts forecast that ALGS's EPS will be -$8.66 for 2025, with the lowest EPS forecast at -$15.99, and the highest EPS forecast at -$1.31. On average, analysts forecast that ALGS's EPS will be -$11.95 for 2026, with the lowest EPS forecast at -$16.95, and the highest EPS forecast at -$8.97. In 2027, ALGS's EPS is forecast to hit -$15.49 (min: -$20.98, max: -$9.99).

What is ALGS's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ALGS) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.